Divalproex Sodium Tablet, Delayed Release
Product Images NDC 50090-7121

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 50090-7121). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Divalproex Fig1)

Figure 1 (Divalproex Fig1)
A bar graph comparing percentage outcomes in two studies, Study 1 (YMRS) and Study 2 (MRS), between placebo (PBO) and divalproex sodium delayed-release tablets (DVPX). The graph shows higher percentages for DVPX (60% and 58%) compared to PBO (26% and 29%), with statistical significance indicated (p < 0.05).*
FDA Label Image

Figure 2 (Divalproex Fig2)

Figure 2 (Divalproex Fig2)
A line graph comparing the percentage reduction in CPS (clinical parameter score) rate against the percentage of patients for Divalproex Sodium Delayed-Release Tablets versus Placebo. The y-axis represents the % reduction in CPS rate from -100% to 100%, while the x-axis shows the percentage of patients from 100% to 0%. The graph indicates treatment effects ranging from worsening to improvement.*
FDA Label Image

Figure 3 (Divalproex Fig3)

Figure 3 (Divalproex Fig3)
A graph titled Figure 3 showing the percentage reduction in CRS rate on the vertical axis versus the percentage of patients on the horizontal axis. Two curves compare effects of high dose (solid line) and low dose (dashed line) treatments, illustrating patient improvement or worsening.*
FDA Label Image

Figure 4 (Divalproex Fig4)

Figure 4 (Divalproex Fig4)
A bar chart titled 'Figure 4 Mean 4-week Migraine Rates' comparing migraine rates between placebo and divalproex sodium delayed-release tablets across two studies. The vertical axis represents migraine rates from 0 to 6. Study 1 shows higher rates for placebo than for divalproex sodium delayed-release tablets at a mean dose of 1,087 mg/day. Study 2 compares placebo with divalproex sodium delayed-release tablets at doses of 500 or 1,000 mg/day, with placebo showing higher migraine rates.*
FDA Label Image

Chemical Structure (Divalproex Str)

Chemical Structure (Divalproex Str)
Chemical structure of Divalproex Sodium depicting its molecular composition with carbon (CH3CH2CH2 and CH2CH2CH3 groups), hydroxyl (HO), sodium ion (Na+), and carboxylate (COO-) components in a polymeric arrangement (indicated by n).*
FDA Label Image

Label Image (Lbl500907121)

Label Image (Lbl500907121)
Label of Divalproex Sodium delayed-release tablets, 125 mg, by A-S Medication Solutions. The label includes the NDC 50090-7121-0, states the product contains 30 tablets, and provides storage instructions to keep between 68 to 77 degrees Fahrenheit. The label also notes that each enteric-coated delayed-release tablet contains Divalproex Sodium USP equivalent to valproic acid 125 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.